Regulatory Aspects for Drug Development

Lisa D Coles, Henrik Klitgaard, Marie Kuker, James C Cloyd

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Translating preclinical epilepsy therapy research into clinical therapeutic products requires an understanding of the regulatory requirements pertaining to drug development. In this chapter, we discuss regulatory considerations in the development of new molecular entities, or the repurposing of approved drugs for the treatment of epilepsy, as an investigator moves a potential drug therapy through discovery, preclinical and clinical development, and approval. We provide an overview of relevant guidances and harmonization by regulatory agencies, and the regulatory process and requirements for studying drugs in humans. Specifically, this chapter summarizes the process for submitting and maintaining an investigation new drug (IND) application, and provides an overview of the required IND content, including preclinical pharmacology and toxicology study summaries; chemistry, manufacturing, and controls information; previous human experience; and the clinical investigation plan. These components are discussed with an emphasis on preclinical testing specific for epilepsy. Last, the topics of repurposing an approved drug and obtaining orphan drug designation are highlighted as special considerations that may be important for investigator-initiated research in epilepsy.

Original languageEnglish (US)
Title of host publicationModels of Seizures and Epilepsy
Subtitle of host publicationSecond Edition
PublisherElsevier Inc.
Pages69-82
Number of pages14
ISBN (Print)9780128040669
DOIs
StatePublished - Jan 1 2017

Fingerprint

Epilepsy
Drug Repositioning
Pharmaceutical Preparations
Orphan Drug Production
Research Personnel
Research
Toxicology
Therapeutics
Pharmacology
Drug Therapy

Keywords

  • Animal models
  • Clinical development
  • Drug development
  • Drug repurposing
  • Epilepsy
  • Investigation new drug application
  • Orphan drug
  • Preclinical development
  • Regulations
  • Regulatory
  • Seizure

Cite this

Coles, L. D., Klitgaard, H., Kuker, M., & Cloyd, J. C. (2017). Regulatory Aspects for Drug Development. In Models of Seizures and Epilepsy: Second Edition (pp. 69-82). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-804066-9.00006-7

Regulatory Aspects for Drug Development. / Coles, Lisa D; Klitgaard, Henrik; Kuker, Marie; Cloyd, James C.

Models of Seizures and Epilepsy: Second Edition. Elsevier Inc., 2017. p. 69-82.

Research output: Chapter in Book/Report/Conference proceedingChapter

Coles, LD, Klitgaard, H, Kuker, M & Cloyd, JC 2017, Regulatory Aspects for Drug Development. in Models of Seizures and Epilepsy: Second Edition. Elsevier Inc., pp. 69-82. https://doi.org/10.1016/B978-0-12-804066-9.00006-7
Coles LD, Klitgaard H, Kuker M, Cloyd JC. Regulatory Aspects for Drug Development. In Models of Seizures and Epilepsy: Second Edition. Elsevier Inc. 2017. p. 69-82 https://doi.org/10.1016/B978-0-12-804066-9.00006-7
Coles, Lisa D ; Klitgaard, Henrik ; Kuker, Marie ; Cloyd, James C. / Regulatory Aspects for Drug Development. Models of Seizures and Epilepsy: Second Edition. Elsevier Inc., 2017. pp. 69-82
@inbook{973b6a876a474c3e902ca7783f9caf71,
title = "Regulatory Aspects for Drug Development",
abstract = "Translating preclinical epilepsy therapy research into clinical therapeutic products requires an understanding of the regulatory requirements pertaining to drug development. In this chapter, we discuss regulatory considerations in the development of new molecular entities, or the repurposing of approved drugs for the treatment of epilepsy, as an investigator moves a potential drug therapy through discovery, preclinical and clinical development, and approval. We provide an overview of relevant guidances and harmonization by regulatory agencies, and the regulatory process and requirements for studying drugs in humans. Specifically, this chapter summarizes the process for submitting and maintaining an investigation new drug (IND) application, and provides an overview of the required IND content, including preclinical pharmacology and toxicology study summaries; chemistry, manufacturing, and controls information; previous human experience; and the clinical investigation plan. These components are discussed with an emphasis on preclinical testing specific for epilepsy. Last, the topics of repurposing an approved drug and obtaining orphan drug designation are highlighted as special considerations that may be important for investigator-initiated research in epilepsy.",
keywords = "Animal models, Clinical development, Drug development, Drug repurposing, Epilepsy, Investigation new drug application, Orphan drug, Preclinical development, Regulations, Regulatory, Seizure",
author = "Coles, {Lisa D} and Henrik Klitgaard and Marie Kuker and Cloyd, {James C}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-804066-9.00006-7",
language = "English (US)",
isbn = "9780128040669",
pages = "69--82",
booktitle = "Models of Seizures and Epilepsy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Regulatory Aspects for Drug Development

AU - Coles, Lisa D

AU - Klitgaard, Henrik

AU - Kuker, Marie

AU - Cloyd, James C

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Translating preclinical epilepsy therapy research into clinical therapeutic products requires an understanding of the regulatory requirements pertaining to drug development. In this chapter, we discuss regulatory considerations in the development of new molecular entities, or the repurposing of approved drugs for the treatment of epilepsy, as an investigator moves a potential drug therapy through discovery, preclinical and clinical development, and approval. We provide an overview of relevant guidances and harmonization by regulatory agencies, and the regulatory process and requirements for studying drugs in humans. Specifically, this chapter summarizes the process for submitting and maintaining an investigation new drug (IND) application, and provides an overview of the required IND content, including preclinical pharmacology and toxicology study summaries; chemistry, manufacturing, and controls information; previous human experience; and the clinical investigation plan. These components are discussed with an emphasis on preclinical testing specific for epilepsy. Last, the topics of repurposing an approved drug and obtaining orphan drug designation are highlighted as special considerations that may be important for investigator-initiated research in epilepsy.

AB - Translating preclinical epilepsy therapy research into clinical therapeutic products requires an understanding of the regulatory requirements pertaining to drug development. In this chapter, we discuss regulatory considerations in the development of new molecular entities, or the repurposing of approved drugs for the treatment of epilepsy, as an investigator moves a potential drug therapy through discovery, preclinical and clinical development, and approval. We provide an overview of relevant guidances and harmonization by regulatory agencies, and the regulatory process and requirements for studying drugs in humans. Specifically, this chapter summarizes the process for submitting and maintaining an investigation new drug (IND) application, and provides an overview of the required IND content, including preclinical pharmacology and toxicology study summaries; chemistry, manufacturing, and controls information; previous human experience; and the clinical investigation plan. These components are discussed with an emphasis on preclinical testing specific for epilepsy. Last, the topics of repurposing an approved drug and obtaining orphan drug designation are highlighted as special considerations that may be important for investigator-initiated research in epilepsy.

KW - Animal models

KW - Clinical development

KW - Drug development

KW - Drug repurposing

KW - Epilepsy

KW - Investigation new drug application

KW - Orphan drug

KW - Preclinical development

KW - Regulations

KW - Regulatory

KW - Seizure

UR - http://www.scopus.com/inward/record.url?scp=85032150613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032150613&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804066-9.00006-7

DO - 10.1016/B978-0-12-804066-9.00006-7

M3 - Chapter

AN - SCOPUS:85032150613

SN - 9780128040669

SP - 69

EP - 82

BT - Models of Seizures and Epilepsy

PB - Elsevier Inc.

ER -